The Commissioning Support Appraisals Service (CSAS) was established to help ensure that PCTs are active and effective consultees, whose contribution to the NICE Technology Appraisal Guidance (TAG) is respected and credible.
This report tells the story of CSAS and its impact and work over the last three years. It also considers the future role to support commissioners in both CCGs and specialised services during 2013/2014.
CSAS rapid evidence reviews can now all be easily accessed by NHS organisations once you have registered to use the website.
CSAS have produced an ACD commentary on NICE ACD: Everolimus - Breast Cancer (HER2 negative, oestrogen receptor positive) - ID 538